Cite
HARVARD Citation
Maimaitili, Y. et al. (2018). An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. Leukemia research. pp. 68-74. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Maimaitili, Y. et al. (2018). An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. Leukemia research. pp. 68-74. [Online].